Business
Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.
For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.
- Published
- (6 days ago)
- Outlet
- MarketWatch
- Section
- Business
- Length here
- Headline and 17-word snippet. The full article is at the source.
More from MarketWatch and around the same time
What gave this city its ‘best place to retire’ crown? You can actually afford to live there.Low cost of living, high quality of life and favorable taxes for retirees, for the win.Dividend stocks are having an excellent October as tech sector strugglesETFs focused on dividend stocks are seeing a powerful rally in October, adding to huge gains in 2026.Options traders are seizing control of the S&P 500There’s a reason the index hasn’t moved much since June, according to a team at UBS.TikTok parent ByteDance’s chatbot is now giving travel-booking sites a run for their money. And yours.Consumers in China are starting to wonder — for good reason — whether the emerging AI travel agents have a hidden agenda.A possible DoorDash-Instacart deal is all about keeping up with Walmart and Amazon, analysts sayThe Wall Street Journal reports that DoorDash was in ‘advanced talks’ to buy Instacart in a deal that would value Instacart at roughly $17 billionWhy Lumentum’s stock led the S&P 500 higher on MondayOptical stocks are staging a comeback following Anthropic’s IPO filing and some other good newsThis page holds the headline and a short snippet as published by MarketWatch, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
